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A B S T R A C T
Purpose
More than two decades ago, an international working group established the International Neuro-
blastoma Response Criteria (INRC) to assess treatment response in children with neuroblastoma.
However, this system requires modiﬁcation to incorporate modern imaging techniques and new
methods for quantifying bone marrow disease that were not previously widely available. The
National Cancer Institute sponsored a clinical trials planning meeting in 2012 to update and reﬁne
response criteria for patients with neuroblastoma.
Methods
Multidisciplinary investigators from 13 countries reviewed data from published trials performed
through cooperative groups, consortia, and single institutions. Data from both prospective and
retrospective trials were used to reﬁne the INRC. Monthly international conference calls were held
from 2011 to 2015, and consensus was reached through review by working group leadership and
the National Cancer Institute Clinical Trials Planning Meeting leadership council.
Results
Overall response in the revised INRC will integrate tumor response in the primary tumor, soft
tissue and bone metastases, and bone marrow. Primary and metastatic soft tissue sites
will be assessed using Response Evaluation Criteria in Solid Tumors (RECIST) and iodine-
123 (123I) –metaiodobenzylguanidine (MIBG) scans or [18F]ﬂuorodeoxyglucose–positron emission
tomography scans if the tumor is MIBG nonavid. 123I-MIBG scans, or [18F]ﬂuorodeoxyglucose–
positron emission tomography scans for MIBG-nonavid disease, replace technetium-99m
diphosphonate bone scintigraphy for osteomedullary metastasis assessment. Bone marrow will
be assessed by histology or immunohistochemistry and cytology or immunocytology. Bonemarrow
with # 5% tumor involvement will be classiﬁed as minimal disease. Urinary catecholamine levels
will not be included in response assessment. Overall response will be deﬁned as complete re-
sponse, partial response, minor response, stable disease, or progressive disease.
Conclusion
These revised criteria will provide a uniform assessment of disease response, improve the in-
terpretability of clinical trial results, and facilitate collaborative trial designs.
J Clin Oncol 35:2580-2587. © 2017 by American Society of Clinical Oncology
INTRODUCTION
Neuroblastoma, a cancer of the sympathetic
nervous system, is responsible for 12% of deaths
associated with cancer in children younger than
15 years of age. It is a heterogeneous disease, with
nearly 50% of patients having a high-risk phenotype
characterized by widespread disease dissemination
and poor long-term survival. In contrast, patients
diagnosed with low- or intermediate-risk neuro-
blastoma have excellent long-term survival.1
Collaborative clinical trials have led to im-
proved outcomes for patients with high-risk
neuroblastoma and decreased therapy-related
toxicity in patients with non–high-risk dis-
ease.2-11 Unfortunately, a lack of consensus re-
garding the deﬁnition of clinically relevant disease
Author afﬁliations and support information
(if applicable) appear at the end of this
article.
Published at jco.org on May 4, 2017.
K.K.M and D.V.-C. contributed equally to
this work.
Corresponding author: Julie R. Park, MD,
Seattle Children’s Hospital, 4800
Sandpoint Way NE, Seattle, WA 98105;
e-mail: julie.park@seattlechildrens.org.
© 2017 by American Society of Clinical
Oncology
0732-183X/17/3522w-2580w/$20.00
ASSOCIATED CONTENT
Appendix
DOI: https://doi.org/10.1200/JCO.
2016.72.0177
DOI: https://doi.org/10.1200/JCO.2016.
72.0177
2580 © 2017 by American Society of Clinical Oncology
VOLUME 35 • NUMBER 22 • AUGUST 1, 2017
response has hampered the development of more effective therapy
for high-risk neuroblastoma and impaired our ability to deﬁne the
optimal management for the majority of patients with low- and
intermediate-risk neuroblastoma. Development of more effective
therapeutic approaches for all children with neuroblastoma must
be a primary goal in prospective clinical trials, in which stan-
dardized methods to interpret response are used to efﬁciently
advance therapy for neuroblastoma.
The International Neuroblastoma Response Criteria (INRC)
consensus was last updated in 199312 and has signiﬁcant limi-
tations in accurately deﬁning response at metastatic bone
and bone marrow sites, the most common sites of relapse.13
Since 1993, iodine-123 (123I) metaiodobenzylguanidine (MIBG)
imaging has become widely available and provides more sen-
sitive and speciﬁc imaging of neuroblastoma in soft tissue and
bone sites.14 For MIBG-nonavid neuroblastomas, [18F]ﬂuo-
rodeoxyglucose (FDG) –positron emission tomography (PET) is
also a useful imaging technique.15-18 Limited guidance for
using nuclear medicine modalities for response was included
in the INRC published in 1993. In addition, further experi-
ence quantifying bone marrow disease using morphology and
evolving molecular modalities to accurately quantify minimal
marrow disease provide the basis for better assessment of bone
marrow response.19 Incorporation of these technical advances
and cumulative clinical trial data into an international consensus
on response is needed to identify optimally effective treatment
strategies and facilitate the development of international col-
laborative clinical trials.
In 2005, an International Neuroblastoma Risk Group
(INRG) task force evaluated the prognostic impact of biologic
and clinical data and established criteria for an internationally
accepted risk group classiﬁcation system.20,21 The INRG task
force also released consensus statements on molecular and ra-
diographic techniques and assessment of minimal residual
disease,22-25 setting the stage for the current revision in neu-
roblastoma response criteria. Single-institution retrospective
analyses have conﬁrmed that MIBG imaging rather than ana-
tomic imaging is more likely to detect recurrent disease.14
The New Approaches to Neuroblastoma Clinical Trials Consor-
tium,26-30 Children’s Oncology Group (COG),31-33 International
Society of Pediatric Oncology European Neuroblastoma
(SIOPEN),34 and German Pediatric Oncology and Hematology
(GPOH)35,36 have also piloted novel response criteria in-
corporating MIBG scoring in anatomic sectors for bone me-
tastases and developed deﬁnitions of bone marrow response
using morphology. As a consequence of this previous work,
neuroblastoma investigators are now poised to develop uniform
response criteria using state-of-the-art imaging and molecular
methods.
A National Cancer Institute–appointed executive planning
committee, representing neuroblastoma leadership from COG
and its international counterparts from SIOPEN, GPOH, and
the Japan Children’s Cancer Group, selected a panel of 52 in-
ternational investigators from 13 countries with oncology,
pathology, radiology, nuclear medicine, surgery, biology, and
statistical expertise (Appendix Table A1, online only) to de-
velop and implement a revised consensus response criteria for
neuroblastoma.
METHODS
Methodology for determining response and deﬁnitions of response in
pediatric neuroblastoma were reviewed using the previously published
INRC and results from neuroblastoma clinical trials published from 2005
to 2015 (Appendix Table A2, online only).2-11,14,23,26-28,31-34,37-39 A da-
tabase established by the INRG task force21,40 was used to identify
prevalence and characteristics of metastatic sites of disease at diagnosis in
patients with neuroblastoma.
Response assessment will include anatomic imaging for primary and
metastatic soft tissue disease, nuclear medicine imaging using 123I-MIBG
or FDG-PET for assessment of soft tissue and bone disease and bilateral
bone marrow aspirates and trephine biopsies for assessment of marrow
disease. Tissue biopsies may be used as an adjunct to verify the presence of
viable neuroblastoma or ganglioneuroblastoma that is evaluable for re-
sponse. Urine catecholamine levels will not be used to evaluate response
because of a lack of standardization in specimen collection and analysis and
the inﬂuence of diet on results.41,42
Primary and Metastatic Soft Tissue Disease
Soft tissue disease should be evaluated using either computed to-
mography (CT) or magnetic resonance imaging (MRI) scans to determine
if a lesion is considered measurable.22 Measurement of irregularly shaped
primary tumors in children with neuroblastoma presents signiﬁcant
challenges for assessment of response. The current INRC includes as-
sessment of tumor volumes using three-dimensional reconstructions from
CT and MRI scans.12 Although the availability of three-dimensional re-
constructions from anatomic imaging has increased in recent years, the
trend in the broader ﬁeld of oncology has been away from the use of
multidimensional measurements and toward assessment of response using
change in the single longest dimension. The RECIST guidance, published
in 2000 and revised in 2009, relies on measurement of nonnodal target
lesions based on the longest single diameter,43-46 whereas discrete lymph
nodes are assessed using the short axis as a single dimension.
A multi-institution, retrospective analysis of 229 patients with high-
risk neuroblastoma was conducted to identify the preferred method of
primary tumor response assessment for use in a revision of the INRC.47No
statistically signiﬁcant difference in outcome was observed when com-
paring the use of three-dimensional volumetric measurement versus
RECIST single longest dimension measurement. Given the complexity of
three-dimensional measurement followed by calculation of resultant
volume, primary tumor sites in children should be deﬁned as measurable
in accordance with RECIST criteria, using the single longest dimension in
any orthogonal plane. The RECIST criteria will also be used for deﬁning
measurable soft tissue metastatic lesions and response as deﬁned by
changes in longest dimension for non–lymph node tumor lesions and
changes in the short-axis diameter of malignant lymph nodes.
123I-MIBG in conjunction with anatomic imaging will deﬁne mea-
surable lesions and will be used to assess primary and metastatic soft tissue
tumor response in the majority of patients. Neuroblastoma is a tumor
derived from the sympathetic nervous system, and neuroblastoma cells
typically express the norepinephrine transporter, which mediates active
intracellular uptake of radiolabeled MIBG in approximately 90% of pa-
tients,18 regardless of stage of disease, risk group, or age at presentation.
MIBG is a derivative of guanethidine and a norepinephrine analog, which
is highly sensitive and speciﬁc for imaging both primary tumor and
metastatic neuroblastoma when labeled with radioisotopes of iodine.22,23
MIBG uptake resolves when a tumor is necrotic or involutes and often
when maturation occurs (only 20% of ganglioneuromas concentrate
MIBG).48 In patients whose tumors do not concentrate MIBG, FDG-PET
is an alternativemodality for tumor detection, although FDG is less speciﬁc
than MIBG because of uptake of FDG in inﬂammatory lesions, as well
as normal and cytokine-stimulated bone marrow.15-17,49 Because FDG is
less speciﬁc for neuroblastoma, a tissue biopsy of at least one of the lesions
may be required to conﬁrm that FDG-avid, MIBG-nonavid lesions are
jco.org © 2017 by American Society of Clinical Oncology 2581
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histologically conﬁrmed to be neuroblastoma and/or ganglioneuro-
blastoma. Adding the use of 123I-MIBG or FDG to the RECISTresponse by
CTor MRI will provide a more speciﬁc and sensitive deﬁnition of response
for soft tissue lesions in neuroblastoma.
Both 123I-MIBG and FDG-PETscans must be interpreted carefully in
light of physiologic sites of uptake. MIBG will normally concentrate in
salivary glands, myocardium, liver, intestines, and brown fat and is excreted
via the urinary tract. FDG is concentrated in the brain, myocardium, liver,
and brown fat and is excreted via the urinary tract. Questions about uptake
in tumor versus physiologic uptake or uptake in soft tissue versus bone are
commonly resolved with three-dimensional imaging with combined
123I-MIBG single-photon emission computed tomography (SPECT; or
MIBG-SPECT/CT) or FDG-PET/CT.15,24,49 Three-dimensional imaging
may also identify lesions not seen with planar imaging. If a three-
dimensional imaging modality is available and used at baseline, this
same modality must be used for all disease response evaluations to
ensure appropriate comparisons. In some cases, however, patients may
require a biopsy in addition to nuclear imaging to conﬁrm the presence
of viable tumor.
MIBG uptake (or FDG for tumors that are not MIBG avid) will be
used to determine which metastatic soft tissue lesions considered mea-
surable by RECIST will be deemed target lesions for response assessment
(Table 1). Nontarget soft tissue lesions will include leptomeningeal tumor,
tumor in cerebrospinal ﬂuid, ascites, or pleural effusion, and lesions smaller
than 10 mm that are considered likely to be active tumor based on clinical
correlation (eg, hepatic and pulmonary nodules). Small (, 10 mm) soft
tissue lesions and lymph nodes that measure shorter than 15 mm on short
axis will be considered nontarget lesions if they are biopsied and proven to
consist of viable tumor. Non–lymph node soft tissue lesions at least 10 mm
in diameter and lymph nodes larger than 15 mm on short axis that are not
MIBG or FDG avid and do not contain viable tumor (if biopsied) will not be
considered either target or nontarget lesions.
For certain subgroups of patients with localized tumors with fa-
vorable histology and genomics, differentiation of the tumor can occur
during therapy and can be associated with an apparent increase in the size
of the tumor, as well as persistent MIBG uptake.48 In the absence of new
tumor sites, serial evaluation of histology may be helpful to accurately
deﬁne response.
Metastatic Bone Disease
Because of its higher sensitivity and speciﬁcity, 123I-MIBG uptake
will replace technetium-99m (99mTc) bone scintigraphy for evaluation
of response at osteomedullary lesions.22,23,50 For patients whose tumors
do not concentrate MIBG, FDG-PET or PET/CT scan will be used for
tumor detection in bone. Anatomic imaging will not be used to evaluate
osteomedullary lesions, because these lesions may not shrink in size
using CT/MRI even in the absence of residual viable tumor. In addition,
osseous lesions without a soft tissue mass are considered nonmea-
surable by RECIST. The measurable extramedullary soft tissue com-
ponents of bone lesions will be assessed using the same criteria used for
other soft tissue sites.
Metastatic Bone Marrow Disease
Assessment of bonemarrow involvement is achieved via evaluation of
bilateral aspirates and bilateral trephine biopsies, a total of four sampled
sites. The 1993 INRC on bone marrow response are based on the number
of sites positive for tumor but do not incorporate modern techniques to
better quantitate disease burden within the bone marrow. The revised
guidelines require assessment of bone marrow aspirates and trephines for
neuroblastoma cells using morphologic criteria in conjunction with ap-
propriate antibodies to conﬁrm the identity of neuroblastoma cells by
immunocytology (if available) and/or immunohistochemistry. Only bone
marrow samples of suitable quality should be investigated, as detailed by
Burchill et al.19 Although more advanced techniques, including automatic
immunoﬂuorescence plus ﬂuorescent in situ hybridization51 and reverse
transcription quantitative polymerase chain reaction (RTqPCR),4,52-57 are
available for assessment of bone marrow status, further prospective val-
idation across clinical trials using standardized reporting is required before
these can be incorporated into a revised INRC.
RESULTS
Data collected by the INRG task force was used to evaluate char-
acteristics of metastatic disease at diagnosis in neuroblastoma.21,40
This database consists of clinical data from 17,938 patients di-
agnosed with neuroblastoma from 1974 to 2015. Speciﬁcs of
metastatic disease sites were not identiﬁed in 11,430 patient cases.
Of the remaining 6,508 patients, 3,496 (54%) had documented
metastatic disease at diagnosis. Bone marrow (n = 1,940; 56%)
and bone (n = 1,625; 47%) are the most common sites of
metastatic disease, highlighting the importance of including these
sites as components of the proposed revised response criteria.
Metastatic disease involving soft tissue sites includes lymph nodes
(n = 846; 24%), liver (n = 727; 21%), and, less commonly, skin
(n = 155; 4%), lung (n = 101; 3%), and CNS (n = 38; 1%).
On the basis of review of the scientiﬁc literature and consensus
among the experts of this panel, the following revised INRC are
proposed. Response will be based on all components of disease,
taking into consideration soft tissue, bone, and bone marrow
disease sites.
Primary Tumor
Response of primary tumor using both RECIST criteria and
MIBG (or FDG if tumor is MIBG nonavid) uptake will be used
(Table 2). In patients with bilateral adrenal lesions, response will be
Table 1. Key Terms
Term Deﬁnition
Target lesions Disease sites that meet criteria of
measurable size (nonlymphoid soft
tissue mass $ 10 mm in longest
dimension or lymph node$ 15mm
in short axis) as well as either
uptake onMIBG (or FDG for MIBG-
nonavid tumors) OR biopsy
positive for neuroblastoma or
ganglioneuroblastoma
Nontarget lesions Lesions that are considered to be
active tumor sites but do not meet
target lesion criteria*
Discrete lymph node Single lymph node that can be
discretely identiﬁed (ie, a cervical
node); measure by short axis
Sum of diameters Sum of the short axis of discrete
lymph nodes (ie, cervical, axillary
nodes) added to the sum of the
longest diameters of non–lymph
node soft tissue metastases;
conglomerate masses of
nondiscrete lymph nodes (ie,
multiple contiguous retroperitoneal
nodes) will be measured using
longest diameter
Abbreviations: FDG, [18F]ﬂuorodeoxyglucose; MIBG, metaiodobenzylguanidine.
*Examples include leptomeningeal tumor, tumor in cerebrospinal ﬂuid, ascites,
and pleural effusion cytology.
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based on the sum of the longest dimensions of both sites unless
biopsy proves one to be ganglioneuroma. In patients with mul-
tifocal nonadrenal disease, the largest tumor will be considered the
primary tumor, and additional lesions will be assessed as metastatic
sites unless biopsy proven to be ganglioneuroma.
In some patients, it may be difﬁcult to distinguish post-
operative changes in soft tissues in the primary tumor bed from
true residual neuroblastoma using anatomic imaging alone. This is
particularly true when residual soft tissue masses are small (, 1 cm
at longest diameter). For this reason, patients with MIBG-nonavid
lesions measuring less than 1 cm in diameter would be considered
to have achieved complete response (CR) in the primary site if the
tumor was initially MIBG avid. For patients with MIBG-nonavid
tumors at the time of diagnosis, small residual tumors must not
demonstrate increased metabolic activity by FDG-PET imag-
ing and, if biopsied, must not demonstrate neuroblastoma or
ganglioneuroblastoma.
Metastatic Soft Tissue and Bone Disease
A combination of anatomic imaging and radionuclide scans
will be used to assess response in soft tissue (including lymph node
and non–lymph node) and bone metastases (Table 3). MIBG
semiquantitative scoring systems have been previously used for
response assessment,37,50,58-62 with international consensus de-
veloped for use of these scoring systems in disease response.23
Although differences exist in the approach to absolute scoring in
the various systems, comparisons of the relative scores as deﬁned
by the SIOPEN scoring system62 and the Curie scoring system61
(used in COG) have yielded consistent designations of response
and have validated MIBG relative scoring as prognostic for overall
response and patient outcome in patients with newly diagnosed
neuroblastoma.36 The consensus recommendation is to use the
MIBG relative score on bone sectors (the absolute score of bone
lesions at time of response assessment divided by the absolute
score of bone lesions at baseline before therapeutic interventions)
for response assessment. The same scoring method (eg, Curie,
SIOPEN) should be used at each time point of response assess-
ment. MIBG-SPECTor MIBG-SPECT/CTmay be used for scoring
purposes, but the same imaging methodology should be used for
all evaluations.
Bone Marrow Metastases
Exact quantiﬁcation of bone marrow involvement at all
sites should be reported; the percentage of tumor inﬁltration of
bone marrow space assessed by histologic evaluation of trephine
or biopsy (with immunohistochemical staining encouraged) or
Table 2. Primary (soft tissue) Tumor Response*
Response Anatomic + MIBG (FDG-PET†) Imaging
CR , 10 mm residual soft tissue at primary
site AND
Complete resolution of MIBG or FDG-
PET uptake (for MIBG-nonavid tumors)
at primary site
PR $ 30% decrease in longest diameter of
primary site AND
MIBG or FDG-PET uptake at primary site
stable, improved, or resolved
PD . 20% increase in longest diameter
taking as reference the smallest sum
on study (this includes the baseline
sum if that is the smallest on study)
AND
Minimum absolute increase of 5 mm in
longest dimension‡
SD Neither sufﬁcient shrinkage for PR nor
sufﬁcient increase for PD at the
primary site
Abbreviations: CR, complete response; FDG, [18F]ﬂuorodeoxyglucose; MIBG,
metaiodobenzylguanidine; PD, progressive disease; PET, positron emission
tomography; PR, partial response; SD, stable disease.
*Not for use in assessment of metastatic sites.
†Used for MIBG-nonavid tumors.
‡Mass that does not meet PD measurement criteria but has ﬂuctuating MIBG
avidity will not be considered PD.
Table 3. Tumor Response at Metastatic Soft Tissue and Bone Sites
Response Anatomic + MIBG (FDG-PET*) Imaging
CR Resolution of all sites of disease, deﬁned as:
Nonprimary target and nontarget lesions measure , 10 mm
AND
Lymph nodes identiﬁed as target lesions decrease to a short
axis , 10 mm AND
MIBG uptake or FDG-PET uptake (for MIBG-nonavid tumors) of
nonprimary lesions resolves completely
PR $ 30% decrease in sum of diameters† of nonprimary target
lesions compared with baseline AND all of the following:
Nontarget lesions may be stable or smaller in size AND
No new lesions AND
$ 50% reduction in MIBG absolute bone score (relative MIBG
bone score $ 0.1 to # 0.5) or $ 50% reduction in number of
FDG-PET–avid bone lesions‡§
PD Any of the following:
Any new soft tissue lesion detected by CT/MRI that is also
MIBG avid or FDG-PET avid
Any new soft tissue lesion seen on anatomic imaging that is
biopsied and conﬁrmed to be neuroblastoma or
ganglioneuroblastoma
Any new bone site that is MIBG avid
A new bone site that is FDG-PET avid (for MIBG-nonavid
tumors) AND has CT/MRI ﬁndings consistent with tumor OR
has been conﬁrmed histologically to be neuroblastoma or
ganglioneuroblastoma
. 20% increase in longest diameter taking as reference the
smallest sum on study (this includes the baseline sum if that
is the smallest on study) AND minimum absolute increase of
5 mm in sum of diameters of target soft tissue lesions
Relative MIBG score $ 1.2§
SD Neither sufﬁcient shrinkage for PR nor sufﬁcient increase for
PD of nonprimary lesions
Abbreviations: CR, complete response; CT, computed tomography; FDG, [18F]
ﬂuorodeoxyglucose; MIBG, metaiodobenzylguanidine; MRI, magnetic reso-
nance imaging; PD, progressive disease; PET, positron emission tomography;
PR, partial response; SD, stable disease.
*Used for MIBG-nonavid tumors
†Sum of diameters is deﬁned as the sum of the short axis of discrete lymph
nodes (ie, cervical, axillary nodes) added to the sum of the longest diameters of
non–lymph node soft tissue metastases. Masses of conglomerate nondiscrete
lymph nodes will be measured using longest diameter.
‡For patients with soft tissue metastatic disease, resolution of MIBG and/or
FDG-PET uptake at the soft tissue sites is not required; all size reduction criteria
must be fulﬁlled.
§RelativeMIBG score is the absolute score for bone lesions at time of response
assessment divided by the absolute score for bone lesions at baseline before
therapeutic interventions. The same scoring method (eg, Curie or International
Society of Pediatric Oncology European Neuroblastoma) must be used at all
assessment time points. MIBG single-photon emission computed tomography
(SPECT) or MIBG-SPECT/CT may be used for scoring purposes, but the same
imaging methodology should be used for all evaluations.
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counting of the number of tumor cells in aspirates by cytology or
immunocytology (recommended if available) divided by the
number of hematopoietic or mononuclear cells evaluated to
obtain a percentage of involvement (methodology described by
Burchill et al19). The bone marrow sample with the highest
percentage of tumor inﬁltration is used in the response algo-
rithm. Neuroblastoma inﬁltration in the marrow can be het-
erogeneously distributed throughout the skeleton.63,64 Because
the clinical impact of this heterogeneity has not yet been fully
evaluated, detection of more than 0% to # 5% tumor in-
ﬁltration in bone marrow will represent a new category of
minimal disease (Table 4).
Overall Response
Overall response will be deﬁned by combining response of the
individual components (ie, soft tissue, bone, and bone marrow
disease). All components must be evaluated and of sufﬁcient quality
to fully assess overall response (Table 5; Appendix Table A3, online
only). An overall CR requires that all involved components have
a CR. An overall partial response includes a partial response of
all soft tissue and bone sites or noninvolvement in one of these
components but allows residual minimal disease in the bone
marrow. The prior category of mixed response has been elim-
inated, and a new category, minor response, has been included.
Minor response requires a partial response or CR in at least
one component, stable disease for at least one component, and
no evidence of progressive disease in any component. Progres-
sive disease in any one component deﬁnes overall progressive
disease.
DISCUSSION
The INRC revisions described in this consensus statement rep-
resent an evolution of neuroblastoma response criteria, with the
incorporation of functional imaging, the widespread application of
advanced techniques for analysis of marrow involvement, and the
recognition that clinically signiﬁcant minimal bone marrow dis-
ease can be assessed by discontinuous sampling. The goal of the
current INRC revision is to eliminate modalities for tumor as-
sessment that are less sensitive and/or speciﬁc for neuroblastoma
(eg, bone scintigraphy and catecholamine levels) and replace these
with nuclear imaging modalities (123I-MIBG and FDG-PET im-
aging) that increase the likelihood of detection of viable neuro-
blastoma and/or ganglioneuroblastoma in soft tissue and bone
metastatic sites and to include the use of histopathologic tech-
niques that quantitate the extent of bone marrow involvement.
These newer modalities are being widely used; however, until now,
they have not been uniformly incorporated into neuroblastoma
disease assessment. As a result, there have been signiﬁcant chal-
lenges in interpretation of clinical trial results across institutions
and consortia, highlighting the need for revisions to the INRC. In
addition, the prior INRC were developed with a focus on newly
diagnosed neuroblastoma and were not easily applicable to phase I
or II clinical trials for patients with recurrent or refractory disease,
where bone and bone marrow are frequently the only sites of
tumor involvement.
Functional imaging is the cornerstone of these revised
criteria for neuroblastoma response. Bone scintigraphy with
99mTc biphosphonates, although sensitive for detecting osseous
metastatic sites at diagnosis, lacks speciﬁcity when assessing
disease response to therapy, because of tracer uptake in remodeling
bone.65 123I-MIBG imaging provides superior sensitivity com-
pared with bone scintigraphy for detecting viable neuroblas-
toma and will be used for assessment of response of bony
metastatic disease. Postoperative changes in resected soft tissue
sites and therapy-induced tumor differentiation require the use of
functional imaging to complement the use of RECIST guidelines,
which are based on anatomic imaging for response assessment of
soft tissue sites. In the minority of patients with MIBG-nonavid
disease, FDG-PET provides an alternative modality to assess
disease status at primary or metastatic soft tissue sites and bony
Table 4. Bone Marrow Metastasis Response*
Response Cytology†/Histology‡
CR Bone marrow with no tumor inﬁltration on reassessment,
independent of baseline tumor involvement
PD Any of the following:
Bone marrow without tumor inﬁltration that becomes . 5%
tumor inﬁltration on reassessment OR
Bone marrow with tumor inﬁltration that increases by . two-
fold and has . 20% tumor inﬁltration on reassessment
MD Any of the following:
Bone marrow with # 5% tumor inﬁltration and remains . 0 to
# 5% tumor inﬁltration on reassessment OR
Bone marrow with no tumor inﬁltration that
has # 5% tumor inﬁltration on reassessment OR
Bone marrow with . 20% tumor inﬁltration that has . 0 to #
5% tumor inﬁltration on reassessment
SD Bone marrow with tumor inﬁltration that remains positive with
. 5% tumor inﬁltration on reassessment but does not meet
CR, MD, or PD criteria
NOTE. In the case of discrepant results between aspirations or core biopsies
from two or more sites taken at the same time, the highest inﬁltration result
should be reported using the criteria in this table.
Abbreviations: CR, complete response; MD, minimal disease; PD, progressive
disease; SD, stable disease.
*Response will be compared with baseline disease evaluations before en-
rollment in a clinical trial or, for newly diagnosed patients, with baseline at
speciﬁc times during therapy (ie, at diagnosis and before start of therapy, before
speciﬁc phases of therapy such as induction, high-dose chemotherapy with
stem-cell rescue consolidation, or postconsolidation immunotherapy).
†Accompanied by immunocytology (recommended, not mandatory).
‡Accompanied by immunohistochemistry; speciﬁc recommendations included
in article by Burchill et al.19
Table 5. Determination of Overall Response
Response Criterion
CR All components meet criteria for CR
PR PR in at least one component and all other components are
either CR, MD* (bone marrow), PR (soft tissue or bone), or
NI†; no component with PD
MR PR or CR in at least one component but at least one other
component with SD; no component with PD
SD SD in one component with no better than SD or NI† in any other
component; no component with PD
PD Any component with PD
Abbreviations: CR, complete response; MD, minimal disease; MR, minor re-
sponse; NI, not involved; PD, progressive disease; PR, partial response; SD,
stable disease.
*For bone marrow assessment only.
†Site not involved at study entry and remains uninvolved.
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sites. Thus, in contrast to the majority of adult trials that use only
RECIST criteria to deﬁne response, the revised INRC will fully
incorporate the sensitive and speciﬁc nuclear medicine modalities
available to better deﬁne neuroblastoma response.
Bone marrow represents the most common site of meta-
static disease at diagnosis and is one of the most common sites of
relapse in patients with neuroblastoma. The INRC 1993 ver-
sion12 incorporated the number of involved bone marrow sites
(assessing bilateral bone marrow aspirates and biopsies) into
response assessment. However, the level of disease at each site
was not assessed, and no distinction was made between patients
who had a single neuroblastoma cell clump in the bone marrow
and those who had near-complete replacement of the bone
marrow compartment with tumor. Consequently, assessment of
bone marrow response lacked precision, which could lead to
over- or underestimation of response. Bone marrow response
criteria piloted in the NANT consortium27,29-31 and subse-
quently adopted in COG early-phase clinical trials have used the
maximum percentage of tumor found at any of the four sampled
bone marrow sites in response assessment and deﬁned inter-
mittently positive detection of low levels of tumor inﬁltration in
the marrow as stable disease rather than progression. Multiple
published early-phase clinical trials have conﬁrmed the feasibility
of incorporating these criteria to evaluate bone marrow response
assessment in neuroblastoma.27,29-31,33 The revised INRC now
include quantitative assessment of bone marrow involvement, and
the bone marrow response criteria reﬂect the current uncertainty
regarding the clinical impact of detecting intermittent minimal
disease. The optimal methodology for quantiﬁcation of tumor in
bone marrow is still under evaluation. The article by Burchill
et al19 provides details about the methodologies incorporated in
the revised INRC to standardize the deﬁnition of bone marrow
response. The precise amount of tumor cell inﬁltration in bone
marrow aspirates and trephines or biopsies must be collected in
future clinical trials, allowing for better assessment of the re-
lationship between marrow response with overall outcome and
providing data for evidence-based reﬁnement of future revisions
of the INRC.
Because minimal residual marrow disease is frequently
observed post-therapy, these revised response criteria will in-
clude a new categorization of patients with minimal marrow
disease. This will provide the opportunity to more uniformly
study the prognostic importance of minimal disease and the
effect of new agents in the setting of minimal marrow disease.
Furthermore, this new classiﬁcation provides the opportunity to
prospectively study the clinical use of newer techniques, such as
RTqPCR,4,52-57 which provides an objective, rapid throughput
method to precisely quantitate neuroblastoma load in the bone
marrow. Although RTqPCR for neuroblastoma mRNAs has
been shown to be of prognostic and predictive value in several
clinical trials,4,54 it has not yet been widely adopted in clinical
practice and has not been incorporated into these revised INRC.
Additional studies are required to deﬁne how best to incorporate
such highly sensitive detection methods into future reﬁnements
of disease response criteria.
The revised INRC will apply to both newly diagnosed and
recurrent or refractory neuroblastoma. Because these criteria can
be used to assess disease response in patients with only bone and/or
bone marrow metastases, they will enable the evaluation of disease
response in patients without measurable soft tissue disease who are
eligible for early-phase trials.
We anticipate that the INRC will continue to evolve as newer
technologies are incorporated into clinical practice. In addition to
novel techniques for marrow detection, detection of circulating
tumor cells and use of novel functional imaging techniques, such as
diffusion-weighted imaging MRI and PET-MRI, and new radio-
tracers, such as gallium-68–labeled somatostatin analogs,66,67 Iodine-
124–MIBG,68 and [18F]ﬂuorodopa,69 may further provide improved
sensitivity for metastatic tumor detection. As these modalities be-
come more widely available, their incorporation into future INRC
revisions will require prospective study in the context of clinical trials
for the validation of their utility and clinical applicability.
Great strides have been made in using clinical and biologic
characteristics to more precisely assign therapy for children with
neuroblastoma.21 These international consensus response criteria
are an additional step in providing a common international lan-
guage to assess clinical trial outcomes and enhance the opportunity
for international collaborative clinical trials.
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Maris, John Children’s Hospital of Philadelphia,
Philadelphia, PA
Matthay, Kate University of California San Francisco,
San Francisco, CA
McHugh, Kieran Great Ormond Street Hospital for Children,
London, United Kingdom
Mosse, Yael Children’s Hospital of Philadelphia,
Philadelphia, PA
Nakagawara, Akira Saga Medical Center, Koseikan, Japan
Nuchtern, Jed Baylor College of Medicine, Houston, TX
Parisi, Marguerite University of Washington, Seattle, WA
Park, Julie University of Washington, Seattle, WA
Pearson, Andrew Royal Marsden NHS Foundation Trust,
Sutton, United Kingdom
Pﬂuger, Thomas Ludwig Maximilians University of Munich,
Munich, Germany
Potschiger, Ulriche Children’s Cancer Research Institute, Vienna,
Austria
(continued on following page)
jco.org © 2017 by American Society of Clinical Oncology
Revised International Neuroblastoma Response Criteria
Table A1. NCI Clinical Trial Planning Investigators (continued)
Name Institution
Sarnacki, Sabine Hospital Necker-Enfants Malades/Paris
Descartes University, Paris, France
Schleiermacher, Gudrun Institut Curie, Paris, France
Schmidt, Matthias University of Cologne, Cologne, Germany
Scott, Liz Alex’s Lemonade Stand Foundation, Bala
Cynwyd, PA
Seeger, Robert Children’s Hospital of Los Angeles, Los
Angeles, CA
Seibel, Nita National Cancer Institute, Bethesda, MD
Shimada, Hiro Children’s Hospital of Los Angeles, Los
Angeles, CA
Shulkin, Barry St Jude’s Children’s Research Hospital,
Memphis, TN
Simon, Thorsten University of Cologne, Cologne, Germany
Katleen De Preter University of Ghent, Ghent, Belgium
Sposto, Richard Children’s Hospital of Los Angeles, Los
Angeles, CA
Stutterheim, Janine University of Amsterdam, Amsterdam, the
Netherlands
Tytgat, Godelieve Prinses Maxima Center for Pediatric
Oncology, Utrecht, the Netherlands
Valteau-Couanet, Dominique Gustave Roussy, Paris, France
Villablanca, Judy Children’s Hospital of Los Angeles, Los
Angeles, CA
von Schweinitz, Dietrich University of Munich, Munich, Germany
Voss, Stephan Dana-Faber Cancer Institute/Harvard
University, Boston, MA
Wheatley, Keith University of Birmingham, Birmingham,
United Kingdom
Yanik, Greg University of Michigan, Ann Arbor, MI
Abbreviations: NCI, National Cancer Institute; NHS, National Health Service.
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Table A2. Clinical Trials Included in INRG Database
Consortium Clinical Trial
Pediatric Oncology Group POG8742
POG8743
POG9244
POG9243
Children’s Cancer Group CCG321P2/3/4
CCG3891
CCG3881
CCG3951
Children’s Oncology Group A3973
A3961
P9641
ANBL0032
ANBL00P1
ANBL02P1
ANBL0531
ANBL0532
ANBL0931
ANBL00B1
European Neuroblastoma Study Group ENSG IV
ENSG V
ENSG VI
ENSG VIII
Spanish Neuroblastoma Study Group SNSG N-I-87
SNSG N-II-92
Italian Neuroblastoma Study Group NB1992
NB1997
International Society of Pediatric
Oncology European Neuroblastoma
LNESG1
INES
EUNB
German Pediatric Oncology and Hematology NB79
NB82
NB85
NB90
NB95-S
NB97
Japan Study Group for Advanced Neuroblastoma 91A1
Abbreviations: CCG, Children’s Cancer Group; ENSG, European Neuroblastoma
Study Group; EUNB, European Unresectable Neuroblastoma; INES, Infant
Neuroblastoma European Study; INRG, International Neuroblastoma Risk Group;
LNESG1, Localized Neuroblastoma European Study G1; POG, Pediatric On-
cology Group; SNSG, Spanish Neuroblastoma Study Group.
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Table A3. Overall Response Criteria
Primary Tumor
Soft Tissue or Bone Metastatic Disease
(MIBG or FDG-PET)
Bone Marrow Metastatic Disease
(cytology*/histology†) Overall
CR CR CR CR
CR for one response component with either CR or NI for other components CR
CR CR MD PR
CR PR CR PR
CR PR MD PR
CR PR NI PR
CR NI MD PR
PR CR CR PR
PR CR NI PR
PR CR MD PR
PR PR CR PR
PR PR NI PR
PR PR MD PR
PR NI CR PR
PR NI NI PR
PR NI MD PR
NI CR MD PR
NI PR CR PR
NI PR MD PR
CR CR SD MR
CR PR SD MR
CR SD CR MR
CR SD MD MR
CR SD SD MR
CR SD NI MR
CR NI SD MR
PR CR SD MR
PR PR SD MR
PR SD CR MR
PR SD MD MR
PR SD SD MR
PR SD NI MR
PR NI SD MR
SD CR CR MR
SD CR MD MR
SD CR SD MR
SD CR NI MR
SD PR CR MR
SD PR MD MR
SD PR SD MR
SD PR NI MR
SD SD CR MR
SD NI CR MR
NI CR SD MR
NI PR SD MR
NI SD CR MR
SD SD MD SD
NI SD MD SD
SD NI MD SD
NI NI MD SD
SD SD SD SD
SD NI SD SD
SD NI SD SD
NI SD SD SD
NI SD NI SD
NI NI SD SD
PD in any one component PD
Response of not evaluable for any one of the three components that had measurable/evaluable tumor at study enrollment
and no PD for any component
Not evaluable
No response evaluation performed for any of the three components Not done
Abbreviations: CR, complete response; MD, minimal disease; MR, minor response; NI, not involved (site not involved at study entry and remains uninvolved); PD,
progressive disease; PR, partial response; SD, stable disease.
*Accompanied by immunocytology (recommended, not mandatory).
†Accompanied by immunohistochemistry; speciﬁc recommendations included in article by Burchill et al.19
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